Patents by Inventor Rèmi Rabasa-Lhoret

Rèmi Rabasa-Lhoret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Type 2 diabetes biomarkers and uses thereof
    Patent number: 10338081
    Abstract: The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 2, 2019
    Assignees: Caprion Biosciences Inc., Adaerata, Limited Partnership, Val-Chum, Limited Partnership
    Inventors: Eustache Paramithiotis, Marc Prentki, Rèmi Rabasa-Lhoret, Pascal Croteau, Joel Lanoix, S.R. Murthy Madiraju, Èrik Joly
  • TYPE 2 DIABETES BIOMARKERS AND USES THEREOF
    Publication number: 20150330997
    Abstract: The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.
    Type: Application
    Filed: July 30, 2015
    Publication date: November 19, 2015
    Inventors: Eustache Paramithiotis, Marc Prentki, Rèmi Rabasa-Lhoret, Pascal Croteau, Joel Lanoix, S.R. Murthy Madiraju, Érik Joly